Semaglutide stimulates insulin secretion in a glucose-dependent manner, meaning it promotes insulin release only when blood glucose levels are elevated, thereby reducing the risk of hypoglycaemia when used alone
Recent studies suggest that GLP-1 also mediates the metabolic effects of metformin, gut microbiota, and bariatric surgery 3,4,5,6
Observational Efficacy Reports Users self-administering the KLIKGLOW components (or identical 5:1:1 ratios of GHK-Cu, BPC-157, and TB-500) report remarkable physiological benefits that closely align with the theoretical mechanisms outlined in preclinical animal data
Ikuta, N., Sugiyama, H., Shimosegawa, H., Nakane, R., Ishida, Y., Uekaji, Y., Nakata, D., Pallauf, K., Rimbach, G., Terao, K., & Matsugo, S